Key statistics
As of last trade, Kalvista Pharmaceuticals Inc (4XC1:FRA) traded at 10.10, 46.38% above the 52 week low of 6.90 set on Nov 24, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.10 |
---|---|
High | 10.10 |
Low | 10.10 |
Bid | 9.85 |
Offer | 10.50 |
Previous close | 10.00 |
Average volume | 0.00 |
---|---|
Shares outstanding | 43.22m |
Free float | 42.59m |
P/E (TTM) | -- |
Market cap | 484.45m USD |
EPS (TTM) | -3.54 USD |
Data delayed at least 15 minutes, as of Oct 09 2024 07:10 BST.
More ▼
Press releases
- KalVista Pharmaceuticals Presents Sebetralstat Data at the 2024 HAEi Global Angioedema Forum
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema
- KalVista Pharmaceuticals Announces Nine Abstracts Accepted for Presentation at the HAEi Global Angioedema Forum (GAF)
- KalVista Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference
- KalVista Appoints Brian Piekos as Chief Financial Officer
- KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024
- KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update
- KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema
- KalVista Pharmaceuticals Announces Six Abstracts Accepted for Presentation at the 2024 Bradykinin Symposium
More ▼